Crescent Biopharma annual debt-to-equity ratio
2019
2020
2021
2022
2023
2025
Crescent Biopharma Debt-to-Equity Ratio Growth & History (CBIO)
Crescent Biopharma's debt-to-equity ratio was 0.01 for fiscal 2025.
View full Crescent Biopharma company overviewCrescent Biopharma annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.01 | — | — |
| 2023 | 2023-12-31 | 0.02 | −0.00 | −1.65% |
| 2022 | 2022-12-31 | 0.02 | −0.00 | −9.06% |
| 2021 | 2021-12-31 | 0.02 | 0.00 | +7.03% |
| 2020 | 2020-12-31 | 0.02 | −0.00 | −6.43% |
| 2019 | 2019-12-31 | 0.02 | — | — |
Crescent Biopharma quarterly debt-to-equity ratio
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.01 | −0.00 | −25.44% |
| Q1 2026 | 2026-03-31 | 0.01 | — | — |
| Q4 2025 | 2025-12-31 | 0.01 | — | — |
| Q3 2025 | 2025-09-30 | 0.01 | — | — |
| Q2 2025 | 2025-06-30 | 0.01 | −0.01 | −47.22% |
| Q2 2024 | 2024-06-30 | 0.02 | −0.00 | −3.40% |
| Q1 2024 | 2024-03-31 | 0.02 | 0.01 | +108.18% |
| Q4 2023 | 2023-12-31 | 0.02 | −0.00 | −1.65% |
| Q3 2023 | 2023-09-30 | 0.02 | −0.00 | −11.37% |
| Q2 2023 | 2023-06-30 | 0.02 | −0.00 | −10.07% |
| Q1 2023 | 2023-03-31 | 0.01 | −0.01 | −57.56% |
| Q4 2022 | 2022-12-31 | 0.02 | −0.00 | −9.06% |
| Q3 2022 | 2022-09-30 | 0.02 | 0.00 | +9.90% |
| Q2 2022 | 2022-06-30 | 0.03 | 0.00 | +21.29% |
| Q1 2022 | 2022-03-31 | 0.02 | 0.00 | +18.69% |
| Q4 2021 | 2021-12-31 | 0.02 | 0.00 | +7.03% |
| Q3 2021 | 2021-09-30 | 0.02 | 0.00 | +1.86% |
| Q2 2021 | 2021-06-30 | 0.02 | −0.00 | −4.32% |
| Q1 2021 | 2021-03-31 | 0.02 | −0.00 | −9.93% |
| Q4 2020 | 2020-12-31 | 0.02 | −0.00 | −6.43% |
| Q3 2020 | 2020-09-30 | 0.02 | −0.00 | −1.63% |
| Q2 2020 | 2020-06-30 | 0.02 | 0.00 | +1.48% |
| Q1 2020 | 2020-03-31 | 0.02 | 0.00 | +9.15% |
| Q4 2019 | 2019-12-31 | 0.02 | — | — |
| Q3 2019 | 2019-09-30 | 0.02 | — | — |
| Q2 2019 | 2019-06-30 | 0.02 | — | — |
| Q1 2019 | 2019-03-31 | 0.02 | — | — |
Crescent Biopharma debt-to-equity ratio trends
Over the last five fiscal years, Crescent Biopharma's debt-to-equity ratio decreased from 0.02 to 0.01, a change of −0.01. The latest reported quarter, Q2 2026, shows 0.01.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Crescent Biopharma source filings ↗